SIG
PALI icon

Sargent Investment Group’s Palisade Bio PALI Stock Holding History

Sargent Investment Group’s Portfolio PALI Stock Details PALI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-893
Closed -$76K – 203
2022
Q3 		$76K Buy
893
+573
+179% +$121K 0.02% 179
2022
Q2 		$98K Buy
320
+147
+85% +$70.8K 0.03% 178
2022
Q1 		$138K Hold
173
– – 0.03% 179
2021
Q4 		$169K Buy
173
+33
+24% +$57.7K 0.04% 177
2021
Q3 		$278K Buy
+140
New +$309K 0.07% 155

Other funds holding PALI

CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sargent Investment Group's PALI Position: Q4 2022 in Review

Sargent Investment Group sold out of Palisade Bio (PALI) in Q4 2022, closing a stake of 893 shares — an estimated $76K sold.

Sargent Investment Group first reported a position in PALI in Q3 2021 and held it in 5 quarters. The position peaked at $278K in Q3 2021. 11 funds tracked by Wall St. Rank hold PALI as of Q4 2022.

  • Sargent Investment Group reported no remaining Palisade Bio position as of Q4 2022 after selling out during the quarter.
  • Sargent Investment Group sold 893 Palisade Bio shares in Q4 2022, an estimated $76K.
  • Sargent Investment Group first reported a position in Palisade Bio in Q3 2021 and held it in 5 quarters.
  • Sargent Investment Group's Palisade Bio position peaked at $278K in Q3 2021.
  • 11 funds tracked by Wall St. Rank held Palisade Bio as of Q4 2022.

Based on Sargent Investment Group's 13F filing for Q4 2022, filed 31 Jan 2023.